Managed Ventricular Pacing at the Core of New Pacemakers

The FDA has approved Medtronic’s Adapta portfolio of fully automatic pacemakers. The system provides physiologic pacing customized to the needs of individual patients, helping to set new standards of personalized care, the company stated.

The Adapta pacemaker utilizes an exclusive pacing technology called Managed Ventricular Pacing (MVP) that delivers pacing pulses to the heart’s lower right chamber (ventricle) only when necessary, often less than two percent of the time. In addition, the Adapta pacemaker is fully automatic, meaning it continuously monitors, controls and adapts to deliver just the right level of electrical stimulation to the heart without physician interaction.

“For the first time, a pacemaker comes equipped with the combined benefits of Managed Ventricular Pacing and full automaticity,” said Dr. John Andriulli, assistant professor of medicine, director of Arrhythmia Device Program at University of Medicine and Dentistry of N.J., Cooper University Hospital. “Improved customization of pacing means greater safety and better therapy delivery for patients.”

For more information, visit www.medtronic.com.